Olema Oncology Inc is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. The company's lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD), is currently in two Phase 3 clinical trials. In addition, Olema is focused in developing OP-3136, a potent lysine acetyltransferase 6 (KAT6) inhibitor.
Last trade$7.14
Day change-$0.22 (-2.99%)
Day range$7.02 – $7.38
Volume715,792
Market cap$645M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$644.78M
Price / earnings
—
Price / book
1.75×
Price / sales
—
EV / sales
—
EV / EBITDA
-2.38×
Profitability
Earnings per share
-$2.69
Return on assets
-53.49%
Return on equity
-63.97%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.01×
Current ratio
6.12×
Quick ratio
6.12×
Cash ratio
0.69×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$178.44M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for OLMA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$9.93M
$9.39M
$8.75M
$6.86M
$5.93M
$3.96M
$4.25M
$4.47M
Research and development
$67.6M
$57.79M
$49.23M
$43.22M
$39.95M
$43.9M
$30.62M
$32.3M
Total operating expenses
$77.53M
$67.18M
$57.99M
$50.08M
$45.88M
$47.86M
$34.87M
$36.77M
Operating income
-$77.53M
-$67.18M
-$57.99M
-$50.08M
-$45.88M
-$47.86M
-$34.87M
-$36.77M
Interest expense
$0
-$528K
$0
$0
$0
$38K
$0
$0
Income before taxes
-$73.6M
-$63.2M
-$53.09M
-$46.06M
-$42.22M
-$43.78M
-$30.39M
-$33.57M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$73.6M
-$63.2M
-$53.09M
-$46.06M
-$42.22M
-$43.78M
-$30.39M
-$33.57M
Net income attributable to common shareholders
-$73.6M
-$63.2M
-$53.09M
-$46.06M
-$42.22M
-$43.78M
-$30.39M
-$33.57M
EBITDA
-$77.43M
-$67.08M
-$57.87M
-$49.9M
-$45.83M
-$47.73M
-$34.75M
-$36.65M
Basic earnings per share
-$0.73
-$0.61
-$0.52
-$0.50
-$0.49
-$0.51
-$0.36
-$0.51
Diluted earnings per share
-$0.73
-$0.61
-$0.52
-$0.50
-$0.49
-$0.51
-$0.36
-$0.51
Recent news
Company coverage with links to the original publishers.
Olema Pharmaceuticals, Inc. has officially changed its corporate name to Olema Oncology, Inc., effective November 12, 2026. The company's stock will continue trading on Nasdaq under ticker symbol OLMA. The clinical-stage biopharmaceutical company is advancing its lead product candidate palazestrant (OP-1250) through two Phase 3 trials, with top-line data from the OPERA-01 trial expected in Q1 2027.
Olema Pharmaceuticals reported Q3 2026 financial results with $413.8 million in cash and marketable securities. The company is on track to announce top-line data from its pivotal Phase 3 OPERA-01 trial for palazestrant in Q1 2027. Net loss increased to $73.6 million from $42.2 million year-over-year, primarily due to increased enrollment in clinical trials and manufacturing activities. The company appointed Jason O'Byrne as Chief Financial Officer and continues advancing its OP-3136 KAT6 inhibitor program.
Olema Pharmaceuticals announced the appointment of Jason V. O'Byrne as Chief Financial Officer effective August 11, 2026. As part of the appointment, O'Byrne received an employment inducement award of 650,000 stock options with an exercise price of $10.56 per share, vesting over four years with 25% vesting after one year and the remainder vesting monthly over three years.
Olema Oncology announced a clinical trial collaboration with Bayer to evaluate OP-3136, a KAT6 inhibitor, in combination with darolutamide in approximately 36 patients with metastatic castration-resistant prostate cancer. The Phase 1b/2 study is expected to initiate in H2 2026 and represents the first clinical collaboration for OP-3136. Olema will lead the study while maintaining full global commercial rights to OP-3136, with clinical data and inventions jointly owned.
Olema Oncology announced positive Phase 1 clinical data for OP-3136, a KAT6 inhibitor, showing no dose-limiting toxicities, manageable adverse events, and tumor shrinkage in over two-thirds of evaluable patients across multiple solid tumor types. The company plans to continue development as monotherapy and in combination with other agents including palazestrant.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.